CTSO.NASDAQCytosorbents CORP
10-Q: CytoSorbents Corporation Reports First Quarter 2024 Results, Cites Progress in Clinical Trials and Sales Growth
Sentiment:
Quarterly Report
CytoSorbents Corporation announced its first quarter 2024 financial results, highlighting a revenue increase in product sales and progress in clinical trials, while also noting ongoing financial challenges.
Capital raiseThe company has stated that its current cash position is not expected to fund operations beyond the next twelve months, raising substantial doubt about its ability to continue as a going concern.The company is actively pursuing financing sources, including less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof.
Worse than expectedThe company's net loss of $6.36 million was worse than the $7.33 million loss in the same period last year, indicating a lack of improvement in profitability.The company's grant income decreased by 48%, which is a significant decline in a key revenue stream.The company's cash position is not expected to fund operations beyond the next twelve months, raising concerns about its ability to continue as a going concern.
Summary
- CytoSorbents Corporation reported a net loss of $6.36 million for the first quarter of 2024, compared to a net loss of $7.33 million for the same period in 2023.
- Total revenue increased by 4% to $9.79 million, driven by a 14% increase in product sales to $8.99 million, while grant income decreased by 48% to $797,000.
- CytoSorb product sales increased by 14% year-over-year, with distributor sales up 20% and direct sales up 10%.
- The company's gross profit was $6.57 million, with product gross margins at 76%, excluding a one-time inventory adjustment.
- Research and development expenses decreased by $1.97 million to $2.25 million, primarily due to the completion of the STAR-T trial and reduced start-up costs.
- The company's cash and cash equivalents were approximately $8.6 million, with total cash, cash equivalents and restricted cash at $10.1 million as of March 31, 2024.
- The company has stated that its current cash position is not expected to fund operations beyond the next twelve months, raising substantial doubt about its ability to continue as a going concern.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there is positive growth in product sales and progress in clinical trials, the significant net loss, decrease in grant income, and the company's going concern status raise serious concerns. The sentiment is therefore cautiously negative.
Positives
- CytoSorb product sales showed strong growth, increasing by 14% year-over-year.
- The company achieved a 76% product gross margin, indicating improved efficiency.
- Research and development expenses decreased significantly due to the completion of the STAR-T trial.
- The company completed enrollment in the STAR-T trial and presented topline results at the AATS meeting.
- The company is working towards regulatory submissions for DrugSorb-ATR in Q3 2024.
Negatives
- The company reported a net loss of $6.36 million for the first quarter of 2024.
- Grant income decreased by 48% compared to the same period in 2023.
- The company's cash position is not expected to fund operations beyond the next twelve months, raising concerns about its ability to continue as a going concern.
- The STAR-T trial did not meet its primary effectiveness endpoint in the overall patient population.
Risks
- The company's current cash position is not expected to fund operations beyond the next twelve months, raising substantial doubt about its ability to continue as a going concern.
- The company is dependent on securing additional financing to support ongoing operations.
- The STAR-T trial did not meet its primary effectiveness endpoint in the overall patient population, which may impact regulatory approval.
- The company faces risks related to the competitive labor market, rising inflation, and supply chain issues.
- The company is subject to claims and litigation arising in the ordinary course of business, including a recent lawsuit alleging breach of the New Jersey Conscientious Employee Protection Act.
Future Outlook
The company believes the safety and effectiveness data from the STAR-T trial will support the parallel regulatory submission of DrugSorb-ATR to the FDA and Health Canada in the third quarter of 2024. The company is also focused on growing core CytoSorb sales to profitability, reducing cash burn, and maintaining tight control over expenses. The company will need to raise additional capital to support its ongoing operations in the future.
Management Comments
- Management believes that the safety and efficacy results of the STAR-T trial will support regulatory submissions for marketing approval by the FDA and Health Canada.
- Management is focusing on three key objectives: opening the U.S. market, growing core CytoSorb sales, and reducing cash burn.
- Management believes that the company's current cash position is sufficient to fund operations into the fourth quarter of 2024.
Industry Context
The company operates in the medical device industry, specifically in the area of blood purification technologies. The company's products are used in critical care and cardiac surgery settings to treat life-threatening conditions. The company faces competition from other medical device companies in the blood purification market. The company's strategic partnership with Fresenius Medical Care is intended to expand the market reach of CytoSorb.
Comparison to Industry Standards
- The company's product gross margin of 76% is relatively high compared to some medical device companies, but this excludes a one-time inventory adjustment.
- The company's operating loss of $4.93 million is significant, indicating that the company is not yet profitable.
- The company's cash position of $10.1 million is relatively low for a company with ongoing clinical trials and commercial operations, and the company has stated that it is not expected to fund operations beyond the next twelve months.
- The company's reliance on government grants for a portion of its revenue is common in the medical device industry, but the decrease in grant income in Q1 2024 highlights the need for the company to diversify its revenue streams.
- The company's completion of the STAR-T trial and planned regulatory submissions are important milestones for the company, but the failure to meet the primary effectiveness endpoint in the overall patient population is a concern.
- The company's focus on expanding its direct sales territories and strategic partnerships is a common strategy for medical device companies looking to grow their market share.
- The company's development of new products, such as CytoSorb XL and DrugSorb-ATR, is consistent with industry trends of innovation and product development.
Legal Proceedings
- On March 5, 2024, Danielle Greene, a former employee, filed a complaint against the company alleging breach of the New Jersey Conscientious Employee Protection Act (CEPA).
Stakeholder Impact
- Shareholders may be concerned about the company's net loss and going concern status.
- Employees may be concerned about the company's financial stability and future prospects.
- Customers may be concerned about the company's ability to continue supplying its products.
- Creditors may be concerned about the company's ability to repay its debts.
- Suppliers may be concerned about the company's ability to pay for its purchases.
Next Steps
- The company plans to submit regulatory applications for DrugSorb-ATR to the FDA and Health Canada in Q3 2024.
- The company will continue to focus on growing core CytoSorb sales to profitability.
- The company will continue to reduce cash burn and maintain tight control over expenses.
- The company will continue to pursue financing sources to support ongoing operations.
Key Dates
| Date | Description |
|---|---|
| 2003-08-11 | Date of original royalty agreement with an investor. |
| 2013-12-13 | Date of the December 13, 2023 Offering. |
| 2014-12-17 | Date the company's common stock was approved for listing on the Nasdaq Capital Market. |
| 2016-06-03 | Date of original loan agreement with Bridge Bank. |
| 2018-03-29 | Date of the Amended and Restated Loan and Security Agreement with Bridge Bank. |
| 2019-07-31 | Date of the First Amendment to the Amended and Restated Loan and Security Agreement with Bridge Bank. |
| 2020-04-12 | Date of executive employment agreement with Dr. Efthymios Deliargyris. |
| 2020-12-04 | Date of the Third Amendment to the Amended Loan and Security Agreement with Bridge Bank. |
| 2021-03-01 | Date of lease agreement for new operating facility in Princeton, New Jersey. |
| 2021-07-14 | Date the company filed a registration statement on Form S-3 with the SEC. |
| 2021-12-30 | Date the company entered into an Open Market Sale Agreement with Jefferies LLC. |
| 2022-01-19 | Date of the Fourth Amendment to the Amended Loan and Security Agreement with Bridge Bank. |
| 2022-05-01 | Date of three-year preferred supplier agreement with Asklepios. |
| 2022-08-01 | Date of Marketing Agreement with Fresenius Medical Care Deutschland GmbH. |
| 2022-12-27 | Date the company drew down the first $5 million tranche of the Term C loans. |
| 2023-03-31 | Ms. Bloch retired from her role as Chief Financial Officer of the Company. |
| 2023-07-07 | Date of stock option grants to a senior manager. |
| 2023-09-18 | Date of new Employment Agreement with Ms. Kathleen P. Bloch. |
| 2023-12-13 | Date the company closed on a registered direct offering for the sale of common stock and warrants. |
| 2024-01-14 | Date of restricted stock unit grant to an employee. |
| 2024-03-29 | Date of stock option grants to executive officers and certain other non-executive officer employees. |
| 2024-03-31 | End of the reporting period for the first quarter of 2024. |
| 2024-04-02 | Date of stock option and restricted stock unit grants to employees, senior managers, and board members. |
| 2024-04-08 | Date of stock option grants to employees related to the salary reduction program. |
| 2024-04-28 | Date of the presentation of the STAR-T trial results at the AATS meeting. |
| 2024-05-08 | Date of the number of shares of the issuer's common stock outstanding. |
| 2024-05-09 | Date of the filing of the Quarterly Report on Form 10-Q. |
Keywords
CytoSorb, DrugSorb-ATR, blood purification, clinical trial, STAR-T, FDA, regulatory approval, cardiac surgery, cytokine removal, antithrombotic removal, financial results, revenue, gross margin, operating loss, going concern
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.